VPT:CC - Ventripoint to Sponsor DGPK Echo Advanced Workshop
(TheNewswire)
Toronto, Ontario – The Newswire –September 15, 2023 - Ventripoint DiagnosticsLtd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce that it will be a sponsorfor the German Society for Pediatric Cardiology and Congenital HeartDefects Echo Advanced Workshop being held on September 16 th , 2023, in BadOeynhausen. As a sponsor, Ventripoint will have the opportunity toshowcase the VMS+’s AI technology with 2D echo in a practicalhands-on session led by PD Dr. Kai Thorsten Laser.
The German Society for Pediatric Cardiology andCongenital Heart Defects is a non-profit medical society that aims topromote research, diagnostics, and the prevention of congenital andacquired heart disease. The emphasis on education compliments thediagnostic capabilities of Ventripoint’s VMS+, which will behighlighted during the practical session.
The session leader, PD Dr. Laser, is the DeputyDirector and Senior Physician for the Department of PediatricCardiology and Congenital Heart Defects of Herz-und DiabetesszentriumNorth Rhine-Westfalia | HDZ. Dr. Laser’s session will discuss howthe VMS+ is an effective and reliable tool in the assessment ofcongenital heart disease. The session will have a maximum of 30participants so that each physician can receive hands-on learningexperience. The session will discuss twenty different cases and in thepractical portion of the workshop will include patients toinvestigate.
“We are thrilled to have an opportunity for the VMS+to be discussed by someone as knowledgeable about the product as Dr.Laser during the DGPK Echo Advanced Workshop. This workshop willprovide attendees with real life examples of how the VMS+ is apowerful cardiac diagnostic tool,” stated Dr. Alvira Macanovic,President and CEO of Ventripoint Diagnostics.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.